MA-PRECISELY
7.12.2023 15:01:30 CET | Business Wire | Press release
Precisely, the global leader in data integrity, today announced continued momentum for its Precisely Data Integrity Suite. The company has added dozens of customers spanning data integration, data governance, and geo addressing Suite services, with nearly half of global Suite sales attributed to new customer logos. Precisely is helping companies, such as Belfius Bank, Smiley Technologies, UK Power Networks, and Vantage Towers, to quickly build trust in the data they store in modern cloud and hybrid environments. These organizations use this data in AI, advanced analytics, and other high-value, data-driven initiatives to achieve greater operational efficiencies and improved business outcomes.
“In our ongoing commitment to make data easy to discover, understand and use reliably, we are procuring the Precisely Data Integrity Suite,” said Zachary Decent, Data Governance & Quality Manager, Enterprise Data Management at UK Power Networks, providing power to a quarter of the UK’s population. “This move signifies our dedication to fostering Data Best Practice principles, leveraging this platform to offer stakeholders an enriched experience through a comprehensive data catalog, with clearly defined data responsibilities and robust quality monitoring mechanisms.”
"Smiley's Analytics Services depend on a very high level of accuracy for address validation and location data,” said Chris Raper, Chief Strategy Officer, Smiley Technologies Inc., a provider of core banking software and services for community banks and financial institutions. “Leveraging Precisely Data Integrity Suite has allowed us to seamlessly integrate these services into our overall analytics solution supporting Community Banks.”
Research and consulting firm Gartner® identified data integrity as one of four themes in its recent Hype Cycle™ research1. According to the report, “AI relies on data, and better data leads to more reliable AI solutions. Without automated support, validating massive volumes of data is impossible.”
“We chose the Precisely Data Integrity Suite because it will provide us with a strong data governance framework that enables us to leverage trusted data across our organization,” said Sascha Glomski, Manager BI & Finance Transformation, Vantage Towers. “As one of the largest operators of mobile towers in Europe, having end-to-end visibility and a better understanding of our data will help us improve operations, reduce costs, and accelerate time to market.”
In addition to customer traction, Precisely added new partner certifications for the Data Integrity Suite this year. With the Suite, organizations can natively run data integrity processes at scale within leading data cloud environments, such as AWS Redshift, Databricks, Snowflake, and more, accelerating analytics where the data resides.
“Precisely allowed us to scale our integrated data governance and data quality program in order to reach our 2025 ambitions,” said Jérôme Sandron, Head of Data Governance at Belfius Bank, a leading Belgian banking and insurance group.
With the Precisely Data Integrity Suite, businesses harness trusted data to improve customer experiences, increase revenues, reduce costs, and mitigate risk. Comprising interoperable cloud services that share a common data catalog and user experience, the Suite gives organizations confidence their data, wherever it’s stored, has maximum accuracy, consistency, and context. The Data Integrity Suite includes Data Integration, Data Quality, Data Governance, Data Observability, Geo Addressing, Spatial Analytics, and Data Enrichment services.
“The strong customer momentum for the Data Integrity Suite confirms that it is essential to deliver cloud-native data integrity processing,” said Eric Yau, Chief Operating Officer at Precisely. “There is a need for trusted data, and we’re here to solve the complexities for business and data teams alike. We have extensive expertise to provide a clear path for businesses focused on achieving faster insights and optimal efficiencies for their organizations.”
Please visit the Precisely Data Integrity Suite page for more information about data integrity and its benefits.
GARTNER and HYPE CYCLE are a registered trademarks and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
1 Gartner, Hype Cycle for Emerging Technologies in Finance, 2023, July 11, 2023, Mark McDonald
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231207647047/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
